Home » Newsletters » BioWorld Science

BioWorld Science

May 10, 2007

View Archived Issues

Recent patents impart new therapeutic agents for cancer

Recent patents disclose new agents for metabolic disorders

Novel treatment option for respiratory disorders claimed in recent Argenta patent

MEND-CABG II study of MC-1 recommended to continue

CollaGenex discontinues 40 mg cohort in phase II acne study of incyclinide

COSTAR II study fails to meet endpoints

New data indicate Homspera may demonstrate adjuvant capabilities

TorreyPines to sell assets for treating autoimmune diseases to CalciMedica

New bioavailability data for BEMA Fentanyl

Australian TGA accepts Solbec's development plan for Coramsine

Interim three-month data for ISA-247 kidney transplant trial

Preliminary phase IIa data indicate utility of AT-1001 in celiac disease

New data on NX-1207 show sustained symptomatic improvement in BPH

AEterna Zentaris updates clinical progress

European CHMP recommends approval of Siklos

TRPV1 channel as a novel drug target in ocular disorders

Recent clinical data on intravitreal bevacizumab in ophthalmological conditions

Calcineurin inhibitor-free regimen with CP-690550 effective in renal transplantation

Studies show efficacy of lamotrigine in epilepsy

Abatacept associated with reduced flare incidence in juvenile idiopathic arthritis

Vision maintained with combretastatin A-4 in choroidal neovascularization patients

SRI International regains rights to tirapazamine from sanofi-aventis

Omrix seeks Swedish approval for HBIG product

New licensing agreement for NM-702 for arteriosclerosis obliterans

AEterna Zentaris regains rights for cetrorelix from Solvay

Fabre-Kramer amends NDA for gepirone ER in major depressive disorder

Adverse event reported in phase II anemia trial of FG-2216

PAC-113 active in the treatment of oral Candida infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...